Decoquinate is an anticoccidial drug used in poultry production. Its synthesis involves a multi-step process starting from 4-chloro-3-nitrobenzoic acid. Decoquinate acts by inhibiting the growth and development of coccidia parasites, which are single-celled organisms that can cause coccidiosis in chickens. This disease leads to diarrhea, weight loss, and decreased egg production. Decoquinate is important in poultry production as it helps to control coccidiosis and improve the health and productivity of chickens. It is studied to understand its efficacy, safety, and potential environmental impact. The drug has been associated with some concerns regarding potential residues in meat and eggs, as well as possible resistance development in parasites.'
Decoquinate: A coccidiostat for poultry. [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
| ID Source | ID |
|---|---|
| PubMed CID | 29112 |
| CHEMBL ID | 416230 |
| SCHEMBL ID | 43853 |
| MeSH ID | M0005738 |
| Synonym |
|---|
| ethyl 6-decoxy-7-ethoxy-4-hydroxy-quinoline-3-carboxylate |
| deccoxtm |
| 6-decyloxy-7-ethoxy-4-hydroxy-3-quinolinecarboxylic acid ethyl ester |
| nsc-339057 |
| decoxy |
| m and b 15497 |
| 18507-89-6 |
| ethyl 6-(decyloxy)-7-ethoxy-4-hydroxy-3-quinolinecarboxylate |
| m&b 15497 |
| m. and b. 15497 |
| nsc339057 |
| deccox |
| decoquinate |
| hc 1528 |
| deccox (tn) |
| D03667 |
| decoquinate (usp/inn) |
| NCGC00181109-01 |
| einecs 242-389-1 |
| ethyl 6-decyloxy-7-ethoxy-4-hydroxy-3-quinolinate |
| ethyl 5-decyloxy-7-ethoxy-4-hydroxy-3-chinolincarboxylat |
| decoquinatum [inn-latin] |
| decoquinato [inn-spanish] |
| nsc 339057 |
| 3-quinolinecarboxylic acid, 6-(decyloxy)-7-ethoxy-4-hydroxy-, ethyl ester |
| ethyl-6-(decycloxy)-7-ethoxy-4-hydroxy-3-quinolinecarboxylate |
| HMS2093D11 |
| hc-1528 |
| CHEMBL416230 |
| FT-0657664 |
| ethyl 6-decoxy-7-ethoxy-4-oxo-1h-quinoline-3-carboxylate |
| ethyl 6-(decyloxy)-7-ethoxy-4-hydroxyquinoline-3-carboxylate |
| decoquinatum |
| unii-534i52pvwh |
| 534i52pvwh , |
| decoquinato |
| decoquinate [usan:usp:inn:ban] |
| cas-18507-89-6 |
| dtxsid5046851 , |
| tox21_112723 |
| dtxcid3026851 |
| ethyl 4-hydroxy-6-(decyloxy)-7-ethoxyquinoline-3-carboxylate |
| A812918 |
| nsc-759109 |
| nsc759109 |
| pharmakon1600-01505356 |
| D4192 |
| ethyl 6-decyloxy-7-ethoxy-4-hydroxyquinoline-3-carboxylate |
| 6-decyloxy-7-ethoxy-4-hydroxyquinoline-3-carboxylic acid ethyl ester |
| S4145 |
| ethyl 6-decyloxy-7-ethoxy-4-hydroxy-3-quinolinecarboxylate |
| NCGC00264109-01 |
| AKOS015895953 |
| decoquinate [inn] |
| m&b-15497 |
| decoquinate [green book] |
| decoquinate [usan] |
| decoquinate [mi] |
| decoquinate [usp monograph] |
| decoquinate [mart.] |
| decoquinate [usp-rs] |
| AKOS022185844 |
| SCHEMBL43853 |
| NCGC00181109-03 |
| tox21_112723_1 |
| CS-4555 |
| decoquinat |
| JHAYEQICABJSTP-UHFFFAOYSA-N |
| HY-B1036 |
| AB01563292_01 |
| AB01563292_02 |
| 6-(decyloxy)-7-ethoxy-4-hydroxy-3-quinolinecarboxylic acid ethyl ester |
| ethyl 6-(n-decyloxy)-7-ethoxy-4-hydroxyquinoline-3-carboxylate |
| J-521161 |
| SR-05000001968-1 |
| sr-05000001968 |
| decoquinate, vetranal(tm), analytical standard |
| decoquinate, united states pharmacopeia (usp) reference standard |
| F21439 |
| SBI-0206843.P001 |
| Q5249594 |
| mfcd00673686 |
| DB11394 |
| decoquinate 100 microg/ml in acetonitrile/dmf |
| edtadimagnesiumsalt |
| AS-13953 |
| BCP28448 |
| BRD-K17641316-001-01-4 |
| deccox-m medicated powder for whole milk |
| deccoxm |
| decoquinate (mart.) |
| 6-decoxy-7-ethoxy-4-oxo-1h-quinoline-3-carboxylic acid ethyl ester |
| decoquinate, reference standard |
| F90392 |
Dequoquinate is a quinolone derivative that has been used for over 20 years in the control of coccidiosis in domestic ruminants. It is an anticoccidial agent that inhibits respiration in the parasites mitochondrion.
Duoquinate has potential value as a broiler anticoccidial in China and other countries where it has not been previously used. Decoquinate has been studied in all four species.
| Excerpt | Reference | Relevance |
|---|---|---|
| "Decoquinate treats coccidiosis in lambs and calves and prevents coccidiosis in lambs when administered in feed at a dosage of 1 mg decoquinate/kg bodyweight (b.w.) daily for at least 28 days." | ( The history of decoquinate in the control of coccidial infections in ruminants. Bartram, DJ; Taylor, MA, 2012) | 1.45 |
| Excerpt | Reference | Relevance |
|---|---|---|
| " In 6 feedlot trials with 1993 cattle in 5 geographic areas, decoquinate fed at this level for 90-120 days had no adverse effects." | ( Bovine coccidiosis. A review, including field safety studies with decoquinate for prevention. Fox, JE, 1978) | 0.74 |
| Excerpt | Reference | Relevance |
|---|---|---|
| "In this study, a nanoparticle formulation of decoquinate is shown to have superior bioavailability and efficacy in a mouse model of malaria, paving the way to the development of novel, potentially less toxic and more effective therapeutics to combat a disease that still has an enormous impact on a global scale despite the available partially effective therapies." | ( Nanoparticle formulations of decoquinate increase antimalarial efficacy against liver stage Plasmodium infections in mice. Hickman, M; Kozar, MP; Lee, PJ; Li, Q; Melendez, V; Reyes, S; Roncal, N; Wang, H; Xie, L; Zeng, Q; Zhang, J; Zhang, P, 2014) | 0.95 |
| "The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs." | ( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein. Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019) | 0.51 |
Daily treatment with decoquinate at the dosage used in this study did not affect oocyst shedding or clinical signs associated with cryptosporidiosis. Decoquinate nanoformulation was substantially more potent than decoquinates microsuspension in killing both liver and blood stage malarial parasites, proving its potential for therapeutic development.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Daily treatment with decoquinate at the dosage used in this study did not affect oocyst shedding or clinical signs associated with cryptosporidiosis." | ( Prophylactic use of decoquinate for infections with Cryptosporidium parvum in experimentally challenged neonatal calves. Atwill, ER; Brahmbhatt, D; Herrera Alonso, L; Hou, L; Kirk, JH; Miller, TD; Moore, DA; Singer, MD, 2003) | 0.96 |
| " Decoquinate treats coccidiosis in lambs and calves and prevents coccidiosis in lambs when administered in feed at a dosage of 1 mg decoquinate/kg bodyweight (b." | ( The history of decoquinate in the control of coccidial infections in ruminants. Bartram, DJ; Taylor, MA, 2012) | 1.64 |
| " Further in vitro studies utilizing dose-response assays revealed that decoquinate nanoformulation was substantially more potent than decoquinate microsuspension in killing both liver and blood stage malarial parasites, proving its potential for therapeutic development." | ( Nanoparticle formulations of decoquinate increase antimalarial efficacy against liver stage Plasmodium infections in mice. Hickman, M; Kozar, MP; Lee, PJ; Li, Q; Melendez, V; Reyes, S; Roncal, N; Wang, H; Xie, L; Zeng, Q; Zhang, J; Zhang, P, 2014) | 0.93 |
| Protein | Taxonomy | Measurement | Average (µ) | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| RAR-related orphan receptor gamma | Mus musculus (house mouse) | Potency | 2.9789 | 0.0060 | 38.0041 | 19,952.5996 | AID1159521; AID1159523 |
| progesterone receptor | Homo sapiens (human) | Potency | 1.6785 | 0.0004 | 17.9460 | 75.1148 | AID1346784 |
| peripheral myelin protein 22 | Rattus norvegicus (Norway rat) | Potency | 0.0907 | 0.0056 | 12.3677 | 36.1254 | AID624032 |
| Cellular tumor antigen p53 | Homo sapiens (human) | Potency | 0.1188 | 0.0023 | 19.5956 | 74.0614 | AID651631 |
| Spike glycoprotein | Severe acute respiratory syndrome-related coronavirus | Potency | 0.3548 | 0.0096 | 10.5250 | 35.4813 | AID1479145 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
| Assay ID | Title | Year | Journal | Article |
|---|---|---|---|---|
| AID1296008 | Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening | 2020 | SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1 | Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening. |
| AID1346987 | P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen | 2019 | Molecular pharmacology, 11, Volume: 96, Issue:5 | A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein. |
| AID1346986 | P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen | 2019 | Molecular pharmacology, 11, Volume: 96, Issue:5 | A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein. |
| AID504749 | qHTS profiling for inhibitors of Plasmodium falciparum proliferation | 2011 | Science (New York, N.Y.), Aug-05, Volume: 333, Issue:6043 | Chemical genomic profiling for antimalarial therapies, response signatures, and molecular targets. |
| AID1508630 | Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay | 2021 | Cell reports, 04-27, Volume: 35, Issue:4 | A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome. |
| AID1347083 | qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen | 2020 | Antiviral research, 01, Volume: 173 | A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity. |
| AID1347154 | Primary screen GU AMC qHTS for Zika virus inhibitors | 2020 | Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49 | Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors. |
| AID1347091 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SJ-GBM2 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4 | Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347089 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for TC32 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4 | Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347095 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB-EBc1 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4 | Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347100 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for LAN-5 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4 | Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347090 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for DAOY cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4 | Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347093 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-MC cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4 | Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347107 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh30 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4 | Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347097 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Saos-2 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4 | Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347105 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for MG 63 (6-TG R) cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4 | Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347407 | qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Pharmaceutical Collection | 2020 | ACS chemical biology, 07-17, Volume: 15, Issue:7 | High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle. |
| AID1347106 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for control Hh wild type fibroblast cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4 | Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347099 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB1643 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4 | Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347086 | qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal | 2020 | Antiviral research, 01, Volume: 173 | A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity. |
| AID1347424 | RapidFire Mass Spectrometry qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1) | 2019 | The Journal of biological chemistry, 11-15, Volume: 294, Issue:46 | Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens. |
| AID1347098 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-SH cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4 | Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347092 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for A673 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4 | Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347101 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-12 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4 | Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1745845 | Primary qHTS for Inhibitors of ATXN expression | |||
| AID1347096 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for U-2 OS cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4 | Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347102 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh18 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4 | Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347108 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh41 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4 | Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347104 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for RD cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4 | Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347094 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-37 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4 | Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347425 | Rhodamine-PBP qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1) | 2019 | The Journal of biological chemistry, 11-15, Volume: 294, Issue:46 | Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens. |
| AID1347103 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for OHS-50 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4 | Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID651635 | Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression | |||
| AID1347082 | qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal | 2020 | Antiviral research, 01, Volume: 173 | A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity. |
| AID683716 | Antimalarial activity against liver stages of Plasmodium yoelii assessed as inhibition of cytochrome bc1 complex | 2012 | Journal of medicinal chemistry, Feb-09, Volume: 55, Issue:3 | Targeting the liver stage of malaria parasites: a yet unmet goal. |
| AID1304206 | Cytotoxicity against human WI38 cells assessed as growth inhibition after 48 hrs by sulforhodamine B assay | 2016 | Bioorganic & medicinal chemistry letters, 07-01, Volume: 26, Issue:13 | Straightforward conversion of decoquinate into inexpensive tractable new derivatives with significant antimalarial activities. |
| AID1304203 | Antimalarial activity against multidrug resistant Plasmodium falciparum W2 infected in human erythrocytes assessed as inhibition of parasite proliferation after 96 hrs by SYBR Green I fluorescence based assay | 2016 | Bioorganic & medicinal chemistry letters, 07-01, Volume: 26, Issue:13 | Straightforward conversion of decoquinate into inexpensive tractable new derivatives with significant antimalarial activities. |
| AID1304200 | Antimalarial activity against chloroquine-sensitive asexual Plasmodium falciparum NF54 infected in human erythrocytes assessed as inhibition of parasite proliferation at 100 to 500 nM after 96 hrs by SYBR Green I fluorescence based assay | 2016 | Bioorganic & medicinal chemistry letters, 07-01, Volume: 26, Issue:13 | Straightforward conversion of decoquinate into inexpensive tractable new derivatives with significant antimalarial activities. |
| AID683717 | Antimalarial activity against liver stages of Plasmodium yoelii infected in mouse assessed as protection against parasitic infection at 50 mg/kg, po after 7 days | 2012 | Journal of medicinal chemistry, Feb-09, Volume: 55, Issue:3 | Targeting the liver stage of malaria parasites: a yet unmet goal. |
| AID685500 | HARVARD: Cytotoxicity in HepG2 cell line | 2012 | Proceedings of the National Academy of Sciences of the United States of America, May-29, Volume: 109, Issue:22 | Liver-stage malaria parasites vulnerable to diverse chemical scaffolds. |
| AID1304210 | Solubility of compound in water | 2016 | Bioorganic & medicinal chemistry letters, 07-01, Volume: 26, Issue:13 | Straightforward conversion of decoquinate into inexpensive tractable new derivatives with significant antimalarial activities. |
| AID748893 | Antiplasmodial activity against asexual blood stage of Plasmodium falciparum | 2013 | Bioorganic & medicinal chemistry letters, May-15, Volume: 23, Issue:10 | Recent advances in malaria drug discovery. |
| AID1304208 | Lipophilicity, log P of compound | 2016 | Bioorganic & medicinal chemistry letters, 07-01, Volume: 26, Issue:13 | Straightforward conversion of decoquinate into inexpensive tractable new derivatives with significant antimalarial activities. |
| AID748890 | Selectivity ratio of IC50 for human cytochrome b-c1 complex to IC50 for Plasmodium falciparum cytochrome b-c1 complex | 2013 | Bioorganic & medicinal chemistry letters, May-15, Volume: 23, Issue:10 | Recent advances in malaria drug discovery. |
| AID748892 | Antiplasmodial activity against sexual blood stage of Plasmodium falciparum | 2013 | Bioorganic & medicinal chemistry letters, May-15, Volume: 23, Issue:10 | Recent advances in malaria drug discovery. |
| AID53005 | Inhibitory activity against second generation merozoids of Eimeria tenella in chick hepatocyte assay in the presence of iproniazid; value given as 0.004-0.0008 | 1998 | Bioorganic & medicinal chemistry letters, Jun-16, Volume: 8, Issue:12 | 8-Aminoquinolines as anticoccidials--II. |
| AID1304201 | Antimalarial activity against chloroquine-sensitive asexual Plasmodium falciparum NF54 infected in human erythrocytes assessed as inhibition of parasite proliferation after 96 hrs by SYBR Green I fluorescence based assay | 2016 | Bioorganic & medicinal chemistry letters, 07-01, Volume: 26, Issue:13 | Straightforward conversion of decoquinate into inexpensive tractable new derivatives with significant antimalarial activities. |
| AID1304202 | Antimalarial activity against multidrug resistant Plasmodium falciparum K1 infected in human erythrocytes assessed as inhibition of parasite proliferation after 96 hrs by SYBR Green I fluorescence based assay | 2016 | Bioorganic & medicinal chemistry letters, 07-01, Volume: 26, Issue:13 | Straightforward conversion of decoquinate into inexpensive tractable new derivatives with significant antimalarial activities. |
| AID1304198 | Antimalarial activity against chloroquine-sensitive asexual Plasmodium falciparum NF54 infected in human erythrocytes assessed as inhibition of parasite proliferation at 5 uM after 96 hrs by SYBR Green I fluorescence based assay relative to control | 2016 | Bioorganic & medicinal chemistry letters, 07-01, Volume: 26, Issue:13 | Straightforward conversion of decoquinate into inexpensive tractable new derivatives with significant antimalarial activities. |
| AID748894 | Antiplasmodial activity against liver stage of Plasmodium yoelii | 2013 | Bioorganic & medicinal chemistry letters, May-15, Volume: 23, Issue:10 | Recent advances in malaria drug discovery. |
| AID1304204 | Resistance index, ratio of IC50 for multi-drug-resistant Plasmodium falciparum K1 infected in human erythrocytes to IC50 for chloroquine-sensitive asexual Plasmodium falciparum NF54 infected in human erythrocytes | 2016 | Bioorganic & medicinal chemistry letters, 07-01, Volume: 26, Issue:13 | Straightforward conversion of decoquinate into inexpensive tractable new derivatives with significant antimalarial activities. |
| AID685501 | HARVARD: Inhibition of liver stage Plasmodium berghei infection in HepG2 cells | 2012 | Proceedings of the National Academy of Sciences of the United States of America, May-29, Volume: 109, Issue:22 | Liver-stage malaria parasites vulnerable to diverse chemical scaffolds. |
| AID748891 | Inhibition of Plasmodium falciparum cytochrome b-c1 complex | 2013 | Bioorganic & medicinal chemistry letters, May-15, Volume: 23, Issue:10 | Recent advances in malaria drug discovery. |
| AID52998 | Inhibitory activity against second generation merozoids of Eimeria tenella in chick hepatocyte assay in the absence of inhibitor; value given as 0.004-0.0008 | 1998 | Bioorganic & medicinal chemistry letters, Jun-16, Volume: 8, Issue:12 | 8-Aminoquinolines as anticoccidials--II. |
| AID1304205 | Resistance index, ratio of IC50 for multi-drug-resistant Plasmodium falciparum W2 infected in human erythrocytes to IC50 for chloroquine-sensitive asexual Plasmodium falciparum NF54 infected in human erythrocytes | 2016 | Bioorganic & medicinal chemistry letters, 07-01, Volume: 26, Issue:13 | Straightforward conversion of decoquinate into inexpensive tractable new derivatives with significant antimalarial activities. |
| AID53008 | Inhibitory activity against second generation merozoids of Eimeria tenella in chick hepatocyte assay in the presence of Tranylcypromine; value given as 0.004-0.0008 | 1998 | Bioorganic & medicinal chemistry letters, Jun-16, Volume: 8, Issue:12 | 8-Aminoquinolines as anticoccidials--II. |
| AID1304209 | Acidic dissociation constant, pKa of compound | 2016 | Bioorganic & medicinal chemistry letters, 07-01, Volume: 26, Issue:13 | Straightforward conversion of decoquinate into inexpensive tractable new derivatives with significant antimalarial activities. |
| AID1304207 | Selectivity index, ratio of IC50 for human WI38 cells to IC50 chloroquine-sensitive asexual Plasmodium falciparum NF54 infected in human erythrocytes | 2016 | Bioorganic & medicinal chemistry letters, 07-01, Volume: 26, Issue:13 | Straightforward conversion of decoquinate into inexpensive tractable new derivatives with significant antimalarial activities. |
| AID1304199 | Antimalarial activity against chloroquine-sensitive asexual Plasmodium falciparum NF54 infected in human erythrocytes assessed as inhibition of parasite proliferation at 1 uM after 96 hrs by SYBR Green I fluorescence based assay relative to control | 2016 | Bioorganic & medicinal chemistry letters, 07-01, Volume: 26, Issue:13 | Straightforward conversion of decoquinate into inexpensive tractable new derivatives with significant antimalarial activities. |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||||
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 34 (36.17) | 18.7374 |
| 1990's | 12 (12.77) | 18.2507 |
| 2000's | 14 (14.89) | 29.6817 |
| 2010's | 22 (23.40) | 24.3611 |
| 2020's | 12 (12.77) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be strong demand-to-supply ratio for research on this compound.
| This Compound (38.50) All Compounds (24.57) |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 5 (5.05%) | 5.53% |
| Reviews | 3 (3.03%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 91 (91.92%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||